• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

Biogen

brain
Posted inClinical Trials, Neuroscience, Rare/Orphan Diseases

Qalsody: New Drug for Amyotrophic Lateral Sclerosis with SOD1 Mutation

August 2, 2022September 8, 2022

Tofersen and the mixed results of treatment for the deadly neurodegenerative disease.

Enjaymo: First Drug to Treat Cold Agglutinin Disease
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory

Enjaymo: First Drug to Treat Cold Agglutinin Disease

February 9, 2022September 8, 2022

Sutimlimab will reduce the need for red blood cell transfusion due to hemolysis.

Treating Parkinson’s Disease: Betting on Alpha-Synuclein
Posted inClinical Trials, In the Pipeline, Neuroscience

Treating Parkinson’s Disease: Betting on Alpha-Synuclein

January 14, 2022September 8, 2022

The pharmaceutical industry continues to fight hard against the devastating neurodegenerative disease.

brain
Posted inClinical Trials, Neuroscience

Buntanetap: Breakthrough in Treatment of Alzheimer’s and Parkinson’s

January 11, 2022September 8, 2022

Buntanetap acts simultaneously on three neurotoxic proteins responsible for neurodegenerative disorders: amyloid beta, alpha-synuclein, and tau protein.

Biogen to Develop Updated Version of Spinraza
Posted inNeuroscience, Pharma & Biotech, Rare/Orphan Diseases

Biogen to Develop Updated Version of Spinraza

January 5, 2022September 8, 2022

Nusinersen for the treatment of spinal muscular atrophy will get a follow-up.

Biogen
Posted inMergers & Acquisitions, Neuroscience

Samsung Wants to Buy Biogen

December 29, 2021September 8, 2022

The price tag is over $42 billion.

Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Zeposia: New Drug to Treat Relapsing Multiple Sclerosis

April 21, 2021September 8, 2022

Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.

Posts navigation

1 2 Older posts
BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News